脑胶质瘤新型放射性示踪剂的研究进展

doi:10.3969/j.issn.1006-7795.2023.04.001

摘要/Abstract

摘要： 新型正电子发射断层扫描（positron emission tomography, PET）放射性药物在胶质瘤患者诊断和治疗中具有潜在临床应用价值，除了常用的18F-氟代脱氧葡萄糖和氨基酸类示踪剂外，仍需开发新型PET示踪剂用于研究脑胶质瘤的其他生物特征，包括灌注、血管生成、缺氧、神经炎症、细胞增殖以及肿瘤侵袭性等。目前这些放射性药物仍在进一步探索中，并需要通过临床试验进行验证，以实现其在胶质瘤诊疗评估中的临床转化。

关键词: 胶质瘤, 正电子发射断层扫描, 放射性示踪剂, 18F-氟代脱氧葡萄糖, 氨基酸

Abstract: New positron emission tomography （PET） radiopharmaceuticals have potential clinical application value in the diagnosis and treatment of glioma patients. In addition to commonly used 18F-fluorodeoxyglucose and amino acid tracers, it is still necessary to develop new PET tracers for studying other biological characteristics of glioma, including perfusion, angiogenesis, hypoxia, neuroinflammation, cell proliferation, and tumor invasiveness. At present, these radioactive drugs are still being further explored and need to be validated through clinical trials to achieve their clinical conversion in the diagnosis, treatment, and evaluation of gliomas.

Key words: glioma, positron emission tomography （PET）, radioactive tracer, 18F-fluorodeoxyglucose （18F-FDG）, amino acid

中图分类号:

王凯, 袁磊磊, 陈谦, 艾林. 脑胶质瘤新型放射性示踪剂的研究进展[J]. 首都医科大学学报, 2023, 44(4): 511-516.

Wang Kai, Yuan Leilei, Chen Qian, Ai Lin. Research progress of new radioactive tracers for cerebral glioma[J]. Journal of Capital Medical University, 2023, 44(4): 511-516.

参考文献

［1］ Mendichovszky I, Jackson A. Imaging hypoxia in gliomas［J］. Br J Radiol, 2011, 84(Spec Iss 2): S145-S158.
［2］ Fink J R, Muzi M, Peck M, et al. Multimodality brain tumor imaging: MR imaging, PET, and PET/MR imaging［J］. J Nucl Med, 2015, 56(10): 1554-1561.
［3］ Provenzale J M, York G, Moya M G, et al. Correlation of relative permeability and relative cerebral blood volume in high-grade cerebral neoplasms［J］. AJR Am J Roentgenol, 2006, 187(4): 1036-1042.
［4］ Lüdemann L, Warmuth C, Plotkin M, et al. Brain tumor perfusion: comparison of dynamic contrast enhanced magnetic resonance imaging using T1, T2, and T2* contrast, pulsed arterial spin labeling, and H215O positron emission tomography［J］. Eur J Radiol, 2009, 70(3): 465-474.
［5］ Essig M, Shiroishi M S, Nguyen T B, et al. Perfusion MRI: the five most frequently asked technical questions［J］. AJR Am J Roentgenol, 2013, 200(1): 24-34.
［6］ Fan A P, Jahanian H, Holdsworth S J, et al. Comparison of cerebral blood flow measurement with ［15O］-water positron emission tomography and arterial spin labeling magnetic resonance imaging: a systematic review［J］. J Cereb Blood Flow Metab, 2016, 36(5): 842-861.
［7］ Raichle M E, Eichling J O, Straatmann M G, et al. Blood-brain barrier permeability of 11C-labeled alcohols and 15O-labeled water［J］. Am J Physiol, 1976, 230(2): 543-552.
［8］ Walsh M N, Bergmann S R, Steele R L, et al. Delineation of impaired regional myocardial perfusion by positron emission tomography with H2(15)O［J］. Circulation, 1988, 78(3): 612-620.
［9］ Bacharach S L, Libutti S K, Carrasquillo J A. Measuring tumor blood flow with H215O: practical considerations［J］. Nucl Med Biol, 2000, 27(7): 671-676.
［10］ La Fougère C, Suchorska B, Bartenstein P, et al. Molecular imaging of gliomas with PET: opportunities and limitations［J］. Neuro Oncol, 2011, 13(8): 806-819.
［11］ Nariai T, Senda M, Ishii K, et al. Three-dimensional imaging of cortical structure, function and glioma for tumor resection［J］. J Nucl Med, 1997, 38(10): 1563-1568.
［12］ Okada H, Weller M, Huang R, et al. Immunotherapy response assessment in neuro-oncology: a report of the RANO working group［J］. Lancet Oncol, 2015, 16(15): e534-e542.
［13］ Albano D, Giubbini R, Bertagna F. 13N-NH3 PET/CT in oncological disease［J］. Jpn J Radiol, 2019, 37(12): 799-807.
［14］ Zhang X S, Shi X C, Yi C, et al. 13N-NH3 versus F-18 FDG in detection of intracranial meningioma: initial report［J］. Clin Nucl Med, 2011, 36(11): 1003-1006.
［15］ Yi C, Shi X C, Zhang X Z, et al. The role of 13N-ammonia in the differential diagnosis of gliomas and brain inflammatory lesions［J］. Ann Nucl Med, 2019, 33(1): 61-67.
［16］ He Q, Zhang L Q, Zhang B, et al. Diagnostic accuracy of 13N-ammonia PET, 11C-methionine PET and 18F-fluorodeoxyglucose PET: a comparative study in patients with suspected cerebral glioma［J］. BMC Cancer, 2019, 19(1): 332.
［17］ Shi X C, Yi C, Wang X Y, et al. 13N-ammonia combined with 18F-FDG could discriminate between necrotic high-grade gliomas and brain abscess［J］. Clin Nucl Med, 2015, 40(3): 195-199.
［18］ Khangembam B C, Sharma P, Karunanithi S, et al. 13N-ammonia PET/CT for detection of recurrent glioma: a prospective comparison with contrast-enhanced MRI［J］. Nucl Med Commun, 2013, 34(11): 1046-1054.
［19］ Beer A J, Haubner R, Wolf I, et al. PET-based human dosimetry of 18F-galacto-RGD, a new radiotracer for imaging αvβ3 expression［J］. J Nucl Med, 2006, 47(5): 763-769.
［20］ Minamimoto R, Jamali M, Barkhodari A, et al. Biodistribution of the 18F-FPPRGDZ PET radiopharmaceutical in cancer patients: an atlas of SUV measurements［J］. Eur J Nucl Med Mol Imaging, 2015, 42(12): 1850-1858.
［21］ Iagaru A, Mosci C, Mittra E, et al. Glioblastoma multiforme recurrence: an exploratory study of 18F FPPRGD2 PET/CT［J］. Radiology, 2015, 277(2): 497-506.
［22］ Li D L, Zhao X B, Zhang L W, et al. 68Ga-PRGD2 PET/CT in the evaluation of glioma: a prospective study［J］. Mol Pharm, 2014, 11(11): 3923-3929.
［23］ Isal S, Pierson J, Imbert L, et al. PET imaging of 68Ga-NODAGA-RGD, as compared with 18F-fluorodeoxyglucose, in experimental rodent models of engrafted glioblastoma［J］. EJNMMI Res, 2018, 8(1): 51.
［24］ Provost C, Prignon A, Rozenblum-Beddok L, et al. Comparison and evaluation of two RGD peptides labelled with 68Ga or 18F for PET imaging of angiogenesis in animal models of human glioblastoma or lung carcinoma［J］. Oncotarget, 2018, 9(27): 19307-19316.
［25］ Cai W B, Chen K, Mohamedali K A, et al. PET of vascular endothelial growth factor receptor expression［J］. J Nucl Med, 2006, 47(12): 2048-2056.
［26］ Chen K, Cai W B, Li Z B, et al. Quantitative PET imaging of VEGF receptor expression［J］. Mol Imaging Biol, 2009, 11(1): 15-22.
［27］ Hsu A R, Cai W B, Veeravagu A, et al. Multimodality molecular imaging of glioblastoma growth inhibition with vasculature-targeting fusion toxin VEGF121/rGel［J］. J Nucl Med, 2007, 48(3): 445-454.
［28］ Jansen M H, Veldhuijzen Van Zanten S E M, Van Vuurden D G, et al. Molecular drug imaging: 89Zr-bevacizumab PET in children with diffuse intrinsic pontine glioma［J］. J Nucl Med, 2017, 58(5): 711-716.
［29］ Lesniak W G, Chu C Y, Jablonska A, et al. A distinct advantage to intraarterial delivery of 89Zr-bevacizumab in PET imaging of mice with and without osmotic opening of the blood-brain barrier［J］. J Nucl Med, 2019, 60(5): 617-622.
［30］ Roncaroli F, Su Z J, Herholz K, et al. TSPO expression in brain tumours: is TSPO a target for brain tumour imaging?［J］. Clin Transl Imaging, 2016, 4: 145-156.
［31］ Cistaro A, Caobelli F, Quartuccio N, et al. Uncommon 18F-FDG-PET/CT findings in patients affected by limbic encephalitis: hyper-hypometabolic pattern with double antibody positivity and migrating foci of hypermetabolism［J］. Clin Imaging, 2015, 39(2): 329-333.
［32］ Cistaro A, Cuccurullo V, Quartuccio N, et al. Role of PET and SPECT in the study of amyotrophic lateral sclerosis［J］. Biomed Res Int, 2014, 2014: 237437.
［33］ Dupont A C, Largeau B, Santiago Ribeiro M J, et al. Translocator protein-18 kDa (TSPO) positron emission tomography (PET) imaging and its clinical impact in neurodegenerative diseases［J］. Int J Mol Sci, 2017, 18(4): 785.
［34］ Quartuccio N, Van Weehaeghe D, Cistaro A, et al. Positron emission tomography neuroimaging in amyotrophic lateral sclerosis: what is new?［J］. Q J Nucl Med Mol Imaging, 2014, 58(4): 344-354.
［35］ Janczar K, Su Z J, Raccagni I, et al. The 18-kDa mitochondrial translocator protein in gliomas: from the bench to bedside［J］. Biochem Soc Trans, 2015, 43(4): 579-585.
［36］ Junck L, Olson J M, Ciliax B J, et al. PET imaging of human gliomas with ligands for the peripheral benzodiazepine binding site［J］. Ann Neurol, 1989, 26(6): 752-758.
［37］ Buck J R, McKinley E T, Hight M R, et al. Quantitative, preclinical PET of translocator protein expression in glioma using 18F-N-fluoroacetyl-N-(2,5-dimethoxybenzyl)-2-phenoxyaniline［J］. J Nucl Med, 2011, 52(1): 107-114.
［38］ Perrone M, Moon B S, Park H S, et al. A novel PET imaging probe for the detection and monitoring of translocator protein 18 kDa expression in pathological disorders［J］. Sci Rep, 2016, 6: 20422.
［39］ Su Z J, Herholz K, Gerhard A, et al. ［11C］-(R)Pk11195 tracer kinetics in the brain of glioma patients and a comparison of two referencing approaches［J］. Eur J Nucl Med Mol Imaging, 2013, 40(9): 1406-1419.
［40］ Su Z, Roncaroli F, Durrenberger P F, et al. The 18-kDa mitochondrial translocator protein in human gliomas: an 11C-(R)Pk11195 PET imaging and neuropathology study［J］. J Nucl Med, 2015, 56(4): 512-517.
［41］ Takaya S, Hashikawa K Z, Turkheimer F E, et al. The lack of expression of the peripheral benzodiazepine receptor characterises microglial response in anaplastic astrocytomas［J］. J Neurooncol, 2007, 85(1): 95-103.
［42］ Tang D W, Hight M R, McKinley E T, et al. Quantitative preclinical imaging of TSPO expression in glioma using N,N-diethyl-2-(2-(4-(2-18F-fluoroethoxy)phenyl)-5,7-dimethylpyrazolo［1,5-a］pyrimidin-3-yl)acetamide［J］. J Nucl Med, 2012, 53(2): 287-294.
［43］ Choudhary G, Langen K J, Galldiks N, et al. Investigational PET tracers for high-grade gliomas［J］. Q J Nucl Med Mol Imaging, 2018, 62(3): 281-294.
［44］ Blair A, Zmuda F, Malviya G, et al. A novel 18F-labelled high affinity agent for PET imaging of the translocator protein［J］. Chem Sci, 2015, 6(8): 4772-4777.
［45］ James M L, Fulton R R, Vercoullie J, et al. DPA-714, a new translocator protein-specific ligand: synthesis, radiofluorination, and pharmacologic characterization［J］. J Nucl Med, 2008, 49(5): 814-822.
［46］ Unterrainer M, Fleischmann D F, Vettermann F, et al. TSPO PET, tumour grading and molecular genetics in histologically verified glioma: a correlative 18F-GE-180 PET study［J］. Eur J Nucl Med Mol Imaging, 2020, 47(6): 1368-1380.
［47］ Albert N L, Unterrainer M, Fleischmann D F, et al. TSPO PET for glioma imaging using the novel ligand 18F-GE-180: first results in patients with glioblastoma［J］. Eur J Nucl Med Mol Imaging, 2017, 44(13): 2230-2238.
［48］ Gagliardi F, Narayanan A, Reni M, et al. The role of CXCR4 in highly malignant human gliomas biology: current knowledge and future directions［J］. Glia, 2014, 62(7): 1015-1023.
［49］ Hartimath S V, Van Waarde A, Dierckx R A J O, et al. Evaluation of N-［11C］methyl-AMD3465 as a PET tracer for imaging of CXCR4 receptor expression in a C6 glioma tumor model［J］. Mol Pharm, 2014, 11(11): 3810-3817.
［50］ Wang Z, Zhang M R, Wang L, et al. Prospective study of 68Ga-NOTA-NFB: radiation dosimetry in healthy volunteers and first application in glioma patients［J］. Theranostics, 2015, 5(8): 882-889.
［51］ Nadeem Abbas M, Kausar S, Wang F, et al. Advances in targeting the epidermal growth factor receptor pathway by synthetic products and its regulation by epigenetic modulators as a therapy for glioblastoma［J］. Cells, 2019, 8(4): 350.
［52］ Sun J K, Cai L, Zhang K, et al. A pilot study on EGFR-targeted molecular imaging of PET/CT with 11C-PD153035 in human gliomas［J］. Clin Nucl Med, 2014, 39(1): e20-e26.
［53］ Oude Munnink T H, Arjaans M E, Timmer-Bosscha H, et al. PET with the 89Zr-labeled transforming growth factor-β antibody fresolimumab in tumor models［J］. J Nucl Med, 2011, 52(12): 2001-2008.
［54］ Den Hollander M W, Bensch F, Glaudemans A W J M, et al. TGF-β antibody uptake in recurrent high-grade glioma imaged with 89Zr-fresolimumab PET［J］. J Nucl Med, 2015, 56(9): 1310-1314.
［55］ Rhrich M, Loktev A, Wefers A K, et al. IDH-wildtype glioblastomas and grade Ⅲ/Ⅳ IDH-mutant gliomas show elevated tracer uptake in fibroblast activation protein-specific PET/CT［J］. Eur J Nucl Med Mol Imaging, 2019, 46(12): 2569-2580.
［56］ Rhrich M, Floca R, Loi L, et al. FAP-specific PET signaling shows a moderately positive correlation with relative CBV and no correlation with ADC in 13 IDH wildtype glioblastomas［J］. Eur J Radiol, 2020, 127: 109021.
［57］ Beinat C, Alam I S, James M L, et al. Development of ［18F］DASA-23 for imaging tumor glycolysis through noninvasive measurement of pyruvate kinase M2［J］. Mol Imaging Biol, 2017, 19(5): 665-672.
［58］ Beinat C, Patel C B, Haywood T, et al. Human biodistribution and radiation dosimetry of ［18F］DASA-23, a PET probe targeting pyruvate kinase M2［J］. Eur J Nucl Med Mol Imaging, 2020, 47(9): 2123-2130.